You will be redirected to:

Continue
Logo - Kls
Logo - Kls
  • Playbook
  • Services
    Frame clinical development strategies
    Operationalize clinical development
    Implement RWE and Late Phase projects
    Enable life data science boosters
    Reach the next level in digital innovation
  • Insights
  • Technology
  • Careers
  • About us
    Company purpose
    Life science innovation
    Committed Keyrus
    Regulatory compliance
    Investors
    Management team
    Keyrus Group
    Locations

Piloting through a pivotal study in cataract eye surgery helping patients recover their vision

Background

In order to gain FDA (Food & Drug Administration) approval, the sponsor entrusted Keyrus Life Science to conduct the pilot for this drug. Because of the Partnership built on the pilot with the sponsor, they chose Keyrus Life Science as their partner on the follow-up study.

Challenge

Lack of the sponsor's knowledge of the product in the US Marketplace and time deadlines.

Approach

Keyrus Life Science took lessons learned from the pilot to run full service for the study and preparation for FDA submission.

Key results

01
Supported strong regulatory documentation
02
Loteprednol  approved in the United States
03
Strong partnership advancement

Benefits

Having learned from the pilot, and having built a strong partnership, the sponsor believed Keyrus Life Science was the best CRO to manage their expanded study to gain FDA approval. The Loteprednol drug was approved in the US.

What our clients say

We developed a dynamic and trusted partnership model where Keyrus’ team was an expert extension of our clinical development team. I would work with Keyrus again with my most critical studies

Yves G. Leblanc, Ph,D., Director of operations, Sandoz

Share this key play

whatsapptwitter
linkedinfacebookworkplace

More key plays

Medical device approved for Hearing Loss
Accelerate the compliance process of your product portfolio in line with the new Medical Device Regulation (EU 2017/745)
Accelerate the clinical validation of an anti-Covid treatment, thanks to an agile data management
Lower costs & risks associated with indication extensions, thanks to a robust meta-analysis of clinical data
Adapting service platforms (FSP) functionning to fit the client's new outsourcing strategy
Facilitate the provision of an innovative treatment thanks to a Managed Access Program (MAP)
Efficiently conducting a worldwide phase 2 clinical study with multiple partners
Achieving an end-to-end audit approval from Health Canada
Facilitate data mapping to SDTM by leveraging standardisation and A.I.
Speed up the development of clinical study documents
Logo - Kls
Headquarters

157 Rue Anatole France 92593 Levallois-Perret

Phone:+33 (0)1 41 34 10 00

LinkedInKlsInstagram
PlaybookServicesInsightsTechnologyCareersAbout us
Company purposeLife science innovationCommitted KeyrusRegulatory complianceInvestorsManagement teamKeyrus GroupLocations
Legal notice & Terms of use
Privacy policy
Data protection